Tag: anthrax vaccine market share

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Anthrax Vaccine Market Evolve in Terms of Growth and Size by 2029?

The size of the anthrax vaccine market has seen consistent growth over the past few years. It is expected to rise from $11.27 billion in 2024 to $11.77 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.4%. The market growth during the historical period can be attributed to factors such as concerns over biological warfare, demand from the military, instances of anthrax outbreaks, readiness in public health, and biodefense initiatives.

In the coming years, the anthrax vaccine market size is projected to experience consistent growth. Its estimated value will reach “$14 billion by 2029 with a compound annual growth rate (CAGR) of 4.4%. This anticipated growth during the forecast period is mainly driven by global security issues, emerging risks, governmental purchases, and readiness for pandemics. Technological progress, increased accessibility in developing countries, emphasis on next-generation vaccines, expanded governmental stockpiling and cooperative research endeavors are set to be the key trends during the forecast period.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

What factors are expected to fuel Anthrax Vaccine market growth in the coming years?

The escalating occurrence of contagious ailments is predicted to boost the anthrax vaccine market’s expansion. Contagious diseases are health conditions triggered by harmful microorganisms, inclusive of bacteria, viruses, parasites, or fungi. These diseases can transmit directly or indirectly between individuals, often leading to symptoms that vary in severity, sometimes leading to death, influenced by the pathogen and the person’s immune reaction. The rising occurrence of infectious diseases stems from demographic shifts worldwide, urbanization, environmental and land use changes, as well as alterations in human behavior. The anthrax vaccine is primarily employed to defend against anthrax and research is currently investigating its potential for wider use in warding off other infectious diseases through its immunogenic attributes and versatility. For example, the US-based nonprofit organization, the Council on Foreign Relations reported in February 2023 that up to 75% of newly identified or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases originated from zoonotic sources. Additionally, across the globe, zoonoses result in 2.7 million human deaths and 2.5 billion instances of illness every year. Hence, the escalating occurrence of diseases is propelling the anthrax vaccine market’s growth.

The anthrax vaccine market covered in this report is segmented –

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine

2) By Application Type: Animal Use, Human Use

3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels

Subsegments:

1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine

2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine

Which Emerging Trends And Strategic Shifts Are Shaping The Anthrax Vaccine Market?

Main players in the anthrax vaccine market are concentrated on generating innovative vaccines and acquiring FDA authentication. This certification confirms that the vaccine has undergone meticulous clinical trials and is deemed safe for public consumption, safeguarding individuals from potential harmful effects. For example, Emergent BioSolutions Inc., a biopharmaceutical firm based in the United States, received the green light for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), formerly referred to as AV7909, from the U.S. Food and Drug Administration (FDA) in July 2023. The approval relied on data extracted from a Phase 2 trial that analyzed Cyfendus’s lack of interference with antibacterial medicines, and a Phase 3 clinical study that compared the immunogenicity and safety of the vaccine to BioThrax, its predecessor. Moreover, it is essential to create safer and more efficient adjuvants to tackle problems related to reactogenicity and optimize the overall efficacy of anthrax vaccines.

What Are The Most Active Companies In The Anthrax Vaccine Market Today?

Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Which Regional Markets Are Attracting The Most Investment In Anthrax Vaccine?

North America was the largest region in the anthrax vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15511&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Current and Projected Market Size of the Anthrax Vaccine Market Through 2034?#_x000D_

Over the past few years, the anthrax vaccine market has consistently expanded. The market is set to surge from $11.27 billion in 2024 to $11.77 billion in 2025, with a compound annual growth rate (CAGR) of 4.4%. The past growth can be explained by factors such as concerns over bio-weapons, military requirements, anthrax epidemics, public health readiness, and biodefense initiatives._x000D_

_x000D_

The market for the anthrax vaccine is projected to experience consistent expansion in the coming years, with an estimated value of $14 billion by 2029, growing at a compound annual growth rate (CAGR) of 4.4%. This growth within the projection period can be credited to factors such as worldwide security issues, newly emerging threats, initiatives by the government to procure vaccines, and preparations for potential pandemics. The forecast period is also marked by significant trends such as advancements in technology, improved vaccine accessibility in emerging economies, emphasis on next-generation vaccines, increased government hoarding of vaccines, and joint research initiatives._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp_x000D_

_x000D_

#What Are the Primary Drivers Supporting the Market Growth of the Anthrax Vaccine Market?#_x000D_

The increase in infectious diseases is anticipated to drive the growth of the anthrax vaccine market. These diseases are illnesses resulting from pathogenic microorganisms like bacteria, viruses, parasites, or fungi, which can be transmitted directly or indirectly between individuals. The severity of symptoms varies from mild to fatal, depending largely on the individual’s immune response and the specific pathogen. The rise in occurrence of these diseases can be attributed to global demographic changes, urbanization, environmental and land use changes, as well as changes in human behavior. The anthrax vaccine is mainly used for protection against anthrax, but its use is being explored for other infectious diseases due to its immunogenic properties and adaptability. For example, in February 2023, the Council on Foreign Relations, a nonprofit organization from the United States, reported that 75% of newly discovered or emerging infectious diseases (EIDs) and 60% of known infectious diseases originated from animals. Additionally, zoonotic diseases are reported to cause 2.7 million human deaths and 2.5 billion instances of illness annually worldwide. Consequently, the growing prevalence of these diseases is fueling the expansion of the anthrax vaccine market._x000D_

_x000D_

#Which Primary Segments of the Anthrax Vaccine Market Are Driving Growth and Industry Transformations?#_x000D_

The anthrax vaccine market covered in this report is segmented – _x000D_

_x000D_

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine_x000D_

2) By Application Type: Animal Use, Human Use_x000D_

3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels_x000D_

_x000D_

Subsegments:_x000D_

1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine _x000D_

2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=15511&type=smp_x000D_

_x000D_

#Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Anthrax Vaccine Market?# Market?#_x000D_

North America was the largest region in the anthrax vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Most Significant Market Trends in the Anthrax Vaccine Market?#_x000D_

Leading firms in the anthrax vaccine market are concentrating on the creation of innovative products and securing FDA approvals for their vaccines, aiming to guarantee safety, efficacy, and accessibility for those prone to anthrax exposure. An FDA approval ensures that the vaccine has undergone rigorous testing through clinical trials, proving its safety for the public and offering protection against potential undesirable side effects. For example, Emergent BioSolutions Inc., a biopharmaceutical company based in the United States, was given approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), also known as AV7909, from the U.S. Food and Drug Administration (FDA) in July 2023. This approval was based on data collected from a Phase 2 trial that examined any interference of Cyfendus with antibacterial drugs and a Phase 3 clinical study that compared the vaccine’s immunogenicity and safety to BioThrax, the preceding anthrax vaccine. Moreover, it is essential to come up with more secure and effective adjuvants to tackle problems related to reactogenicity and elevate the general effectiveness of anthrax vaccines._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report_x000D_

_x000D_

#What Parameters Are Used to Define the Anthrax Vaccine Market?#_x000D_

The anthrax vaccine is a medical product designed to provide immunity against anthrax, a severe infectious disease caused by the bacterium Bacillus anthracis. The vaccine comprises an inactivated form of the anthrax bacterium or its components, stimulating the body’s immune system to produce antibodies against anthrax toxins. The anthrax vaccine is typically administered through injections, with initial doses followed by booster shots to maintain immunity over time._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15511_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Anthrax Vaccine Market Growth Performance Trended Historically, And What Lies Ahead?

The market size for the anthrax vaccine has experienced robust expansion in the past few years. It is forecasted to increase from $11.27 billion in 2024 to $11.88 billion in 2025, with a compound annual growth rate (CAGR) of 5.4%. This significant growth during the historic period is influenced by factors such as fears of biological warfare, military requirements, occurrences of anthrax, preparation in public health sectors, and biodefense initiatives.

What Is the Forecast for the Anthrax Vaccine Market Size Through 2029?

Forecasted to experience robust growth in upcoming years, the anthrax vaccine market is projected to reach a worth of $14.5 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.1%. The expected escalation during the projection period is largely attributed to global security concerns, the emergence of new threats, and initiatives by the government for procurement. Also contributing to the growth during the forecast period is the pandemic readiness, a surge in government stockpiling, cooperation in research initiatives, and a stronger emphasis on next-generation vaccines. There will also be an increased accessibility in developing nations and innovative technological advancements in this period.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

What are the Key Market Players in Anthrax Vaccine Market and How They’re Evolving?

Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A

What Are the Primary Growth Drivers in the Anthrax Vaccine Market?

The escalation in the occurrence of infectious diseases is projected to catalyze the expansion of the anthrax vaccine market. Such diseases are caused by harmful microorganisms like bacteria, viruses, parasites, or fungi, which can be transmitted directly or indirectly, resulting in symptoms that can vary from mild to severe and can sometimes be lethal, contingent on the pathogen and the individual’s immune response. Factors like changes in the world’s population demographics, urbanization, environmental and land changes, and human behavior adjustments, contribute to the prevalence of infectious diseases. The anthrax vaccine is predominantly used to safeguard against anthrax while possibilities of its wider application in preventing other infectious diseases are being studied by examining its immune-response inducing properties and adaptability. For example, data from the Council on Foreign Relations, a US-based nonprofit organization, in February 2023, revealed that 75% of new or emergent infectious diseases and 60% of recognized infectious diseases stemmed from zoonotic origins. Moreover, zoonoses globally lead to 2.7 million human fatalities and 2.5 billion disease episodes in people annually. Thus, the escalating occurrence of diseases is propelling the anthrax vaccine market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15511&type=smp

What Are the Leading Segments in the Global Anthrax Vaccine Industry?

The anthrax vaccine market covered in this report is segmented –

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine

2) By Application Type: Animal Use, Human Use

3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels

Subsegments:

1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine

2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine

What Are the Key Market Trends in the Anthrax Vaccine Industry?

Major players in the anthrax vaccine market are striving to create innovative products and secure FDA authorization, ensuring their vaccines’ safety, efficacy, and accessibility to those vulnerable to anthrax. Approval by the FDA guarantees thorough testing of the vaccine in clinical trials, confirming its safe usage for the public, and offering protection against possible negative effects. For instance, in July 2023, the US-based biopharmaceutical firm, Emergent BioSolutions Inc., was granted approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), formerly known as AV7909, by the U.S. Food and Drug Administration (FDA). This endorsement was based on data collected from a Phase 2 trial that examined Cyfendus’s non-conflict with antibacterial drugs, and Phase 3 clinical research that compared the vaccine’s immunogenicity and safety to BioThrax, the prior anthrax vaccine. Moreover, the creation of safer and more efficient adjuvants is crucial to solve issues related to reactogenicity and improve the overall performance of anthrax vaccines.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

What Is the Regional Outlook for the Anthrax Vaccine Market?

North America was the largest region in the anthrax vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15511

This Report Delivers Insight On:

1. How big is the anthrax vaccine market, and how is it changing globally?

2. Who are the major companies in the anthrax vaccine market, and how are they performing?

3. What are the key opportunities and risks in the anthrax vaccine market right now?

4. Which products or customer segments are growing the most in the anthrax vaccine market?

5. What factors are helping or slowing down the growth of the anthrax vaccine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the anthrax vaccine industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#How Fast Is The Anthrax Vaccine Market Expected to Grow Between 2025 And 2029?#_x000D_

In recent times, the anthrax vaccine market has seen robust growth. Its expansion from $11.27 billion in 2024 to $11.88 billion in 2025, at a compound annual growth rate (CAGR) of 5.4%, is quite notable. Factors contributing to this growth during the historic timeframe include concerns regarding biological warfare, military needs, anthrax outbreak instances, readiness of public health initiatives, and the implementation of biodefense strategies._x000D_

_x000D_

The market size of the anthrax vaccine is predicted to experience robust growth in the upcoming years, reaching $14.5 billion by 2029 with a compound annual growth rate (CAGR) of 5.1%. The projected growth during this period is driven by a range of factors, including global security issues, burgeoning threats, government procurement drives, and preparation for potential pandemics. The forecast period is poised to witness significant trends such as advancements in technology, improved accessibility in emerging economies, emphasis on developing next-generation vaccines, heightened government stockpiling, and collaborative research initiatives._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp_x000D_

_x000D_

#What Are the Primary Drivers Supporting the Market Growth of the Anthrax Vaccine Market?#_x000D_

An increase in infectious disease occurrence is projected to stimulate the anthrax vaccine market’s expansion in the future. Infectious diseases, which are illnesses triggered by harmful microorganisms like bacteria, viruses parasites, or fungi, can be transmitted directly or indirectly among individuals often causing symptoms that range from mild to severe and could even be fatal. It’s pertinent to consider that these diseases result from changes in global population demographics, urban development, environmental and land use changes, and shifts in human behavior. The anthrax vaccine is essentially used for anthrax prevention, but its prospect of being more extensively used to prevent other infectious diseases is being investigated through research into its immune-inducing properties and adaptability. For instance, in February 2023, the Council on Foreign Relations, a nonprofit organization based in the U.S., stated that up to 75% of new or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases originated from zoonotic sources. Moreover, zoonoses cause 2.7 million human fatalities and result in 2.5 billion disease occurrences in people annually across the globe. Thus, the increasing rate of diseases is fueling the expansion of the anthrax vaccine market._x000D_

_x000D_

#Which Primary Segments of the Anthrax Vaccine Market Are Driving Growth and Industry Transformations?#_x000D_

The anthrax vaccine market covered in this report is segmented –_x000D_

_x000D_

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine_x000D_

2) By Application Type: Animal Use, Human Use_x000D_

3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels_x000D_

_x000D_

Subsegments:_x000D_

1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine_x000D_

2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=15511&type=smp_x000D_

_x000D_

#Which Regions Are Key Players in the Growth of the Anthrax Vaccine Market?#_x000D_

North America was the largest region in the anthrax vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Key Market Trends in the Anthrax Vaccine Market Over the Coming Years?#_x000D_

Leading enterprises in the anthrax vaccine market are prioritizing the advancement of inventive solutions and securing FDA authorization for their vaccines. This guarantees the vaccines’ safety, effectiveness, and accessibility to those exposed to anthrax. By going through rigorous FDA clinical trials, these vaccines are confirmed to be safe for the public, providing protection against possible side effects. An example of this occurred in July 2023 when Emergent BioSolutions Inc., an American biopharmaceutical firm, gained approval for their CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909. The U.S. Food and Drug Administration (FDA) granted this approval based on details from a Phase 2 trial evaluating the non-interference of Cyfendus with antibacterial drugs and a Phase 3 clinical study measuring the vaccine’s immunogenicity and safety against BioThrax, an older anthrax vaccine. In addition, the design of adjuvants that are safer and more effective is crucial in handling issues related to reactogenicity and boosting the overall efficiency of anthrax vaccines._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report_x000D_

_x000D_

#What Parameters Are Used to Define the Anthrax Vaccine Market?#_x000D_

The anthrax vaccine is a medical product designed to provide immunity against anthrax, a severe infectious disease caused by the bacterium Bacillus anthracis. The vaccine comprises an inactivated form of the anthrax bacterium or its components, stimulating the body’s immune system to produce antibodies against anthrax toxins. The anthrax vaccine is typically administered through injections, with initial doses followed by booster shots to maintain immunity over time._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15511_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Major Innovations Are Driving the Accelerated Growth of the Anthrax Vaccine Market?

The escalating occurrence of infectious diseases is projected to fuel the expansion of the anthrax vaccine market. Infectious diseases are illnesses induced by disease-causing microorganisms such as bacteria, viruses, parasites, or fungi that can spread either directly or indirectly among individuals. Effects can range from mild to severe, sometimes leading to death, contingent on the pathogen and the individual’s immunity. The increasing incidence of these diseases stem from factors such as global population shifts, urbanization, environmental and land use changes, and alterations in human behavior. The anthrax vaccine, predominantly used to safeguard against anthrax, is being pushed for wider use in controlling other infectious diseases. This is being facilitated through studies aimed at understanding its immunogenic characteristics and adaptability. For example, data from the Council on Foreign Relations, a US-based nonprofit organization, stated in February 2023 that 75% of new or emerging infectious diseases (EIDs), and 60% of known infectious diseases came from zoonotic sources. Additionally, zoonoses globally lead to 2.7 million human deaths and 2.5 billion disease incidences in people each year. Thus, the surging frequency of diseases is propelling the anthrax vaccine market’s growth.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

How Has the Anthrax Vaccine Market Evolved in Recent Years, and What are the Growth Projections for the Forecast Period?

The anthrax vaccine market has witnessed robust growth in the past few years. The market size is projected to increase from $11.27 billion in 2024 to $11.88 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.4%. The substantial growth during the historic period is largely due to factors such as the fears of biological warfare, requirements from the military, anthrax epidemic incidents, readiness of public health systems, and biodefense initiatives.

The anthrax vaccine market is predicted to experience a significant increase in the coming years, with estimations reaching $14.5 billion in 2029, at a compound annual growth rate (CAGR) of 5.1%. This upturn during the predicted period is due to factors such as global security issues, the rise of emerging threats, government purchasing initiatives, and readiness for pandemics. Noteworthily, during this forecast period, trends like technological improvements, enhanced access in developing nations, attention towards next-gen vaccines, elevated government reserve stash, and shared research contributions are expected to emerge.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15511

What Are the Most Significant Market Trends Transforming theAnthrax Vaccine Market?

Primary industry players in the anthrax vaccine market are concentrating on creating innovative offerings and receiving FDA clearance for their immunizations to ensure safety and effectiveness among individuals who are potentially exposed to anthrax. The approval from the FDA guarantees that the vaccine has undergone stringent clinical trials and is secure for usage by the population, thereby safeguarding them from possible negative effects. For example, Emergent BioSolutions Inc., an American biopharmaceutical company, achieved this approval for their CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), formerly known as AV7909, in July 2023 from the U.S. Food and Drug Administration (FDA). The sanction was based on information derived from a Phase 2 trial that keenly examined Cyfendus’s non-interference with antibacterial medicine and, additionally, Phase 3 clinical study that compared the immunogenicity and safety of the vaccination to BioThrax, the former anthrax vaccine. Furthermore, the creation of safer and more effective adjuvants are essential to resolving issues related to reactogenicity and enhance the overall efficacy of anthrax vaccines.

What Are the Top Market Players Propelling the Growth of theAnthrax Vaccine Industry?

Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Which Primary Segments of the Anthrax Vaccine Market Are Driving Growth and Industry Transformations?

The anthrax vaccine market covered in this report is segmented –

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine

2) By Application Type: Animal Use, Human Use

3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels

Subsegments:

1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine

2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=15511&type=smp

Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Anthrax Vaccine Market?# Market?

North America was the largest region in the anthrax vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Anthrax Vaccine Market 2025, By The Business Research Company:

DTP Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

Dog Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Inactivated Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the anthrax vaccine market?

The anthrax vaccine market has experienced strong growth in recent years. It will increase from $11.27 billion in 2024 to $11.88 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth is attributed to concerns about biological warfare, military demand, anthrax outbreaks, public health preparedness, and biodefense programs.

What will be the anthrax vaccine market size in the future?

The anthrax vaccine market is projected to grow strongly, reaching $14.5 billion by 2029 at a CAGR of 5.1%. Growth is driven by global security concerns, emerging threats, government procurement initiatives, and pandemic preparedness. Key trends include technological advancements, greater vaccine accessibility in developing countries, next-generation vaccines, increased government stockpiling, and collaborative research efforts.

Get your anthrax vaccine market report here!

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

What main drivers are fueling expansion in the anthrax vaccine market?

The increasing prevalence of infectious diseases is expected to fuel the growth of the anthrax vaccine market. Infectious diseases, which are caused by microorganisms such as bacteria, viruses, or fungi, are becoming more common due to demographic shifts, urbanization, environmental changes, and altered human behavior. The anthrax vaccine helps protect against anthrax and may be used more broadly in preventing other infectious diseases. Research indicates that zoonotic diseases, which can spread from animals to humans, cause millions of fatalities each year, thus driving the demand for the anthrax vaccine.

What key areas define the segmentation of the global anthrax vaccine market?

The anthrax vaccine market covered in this report is segmented –

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine

2) By Application Type: Animal Use, Human Use

3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels

Subsegments:

1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine

2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

Who are the dominant players expanding their reach in the anthrax vaccine market?

Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A

How are evolving market trends shaping anthrax vaccine Strategies?

In the anthrax vaccine market, companies are focusing on obtaining FDA approvals for their products to ensure safety and efficacy. For example, in July 2023, Emergent BioSolutions received FDA approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909. This approval ensures the vaccine’s safety and effectiveness, helping protect against anthrax exposure.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15511

Which regions are emerging as leaders in the anthrax vaccine market?

North America was the largest region in the anthrax vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

DTP Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

Dog Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Inactivated Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What CAGR Will the Anthrax Vaccine Market Achieve During 2025–2034, and What Does It Indicate?

Over recent years, the anthrax vaccine market has seen a promising growth. Its size is expected to rise from $11.27 billion in 2024 to $11.88 billion in 2025, denoting a compound annual growth rate (CAGR) of 5.4%. This notable expansion in the previous period is mainly due to factors such as anxiety over biological warfare, demand from military sectors, anthrax epidemics, public health readiness, and the implementation of biodefense strategies.

In the coming years, the anthrax vaccine market is anticipated to experience robust growth, expanding to $14.5 billion in 2029 with a compound annual growth rate (CAGR) of 5.1%. This growth prediction for the forecast period can be credited to worldwide security issues, the emergence of new threats, government buying initiatives, and readiness for pandemics. The forecast period is expected to see major trends such as technological innovation, better access in developing countries, emphasis on the development of next-gen vaccines, increased government storage, and cooperative research initiatives.

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Anthrax Vaccine Market?

As the incidence of infectious diseases rises, so too does the anticipated growth of the anthrax vaccine market. These diseases, caused by harmful microorganisms like bacteria, viruses, fungi, or parasites, can spread either directly or indirectly between individuals. Their effects can be anywhere from mild to severe, and in some cases, even lethal, depending on both the pathogen in question and the response of the person’s immune system. The rising occurrence of such diseases is a consequence of numerous factors, including population demographic shifts, urban development, environmental and land-use alterations, and changes in human behaviour. The anthrax vaccine chiefly serves as a protection against anthrax, but ongoing research is investigating its potential wider use in thwarting other infectious diseases, informed by its immunogenic properties and adaptability. For example, it was noted by the US-based non-profit group Council on Foreign Relations in 2023, that up to 75% of newly discovered or emerging infectious diseases (EIDs), and 60% of acknowledged infectious maladies emerged from zoonotic origins. Across the globe, these zoonotic infections lead to an approximate 2.7 million human deaths and 2.5 billion instances of human sickness annually, hence driving the anthrax vaccine market’s growth due to the escalating incidence of diseases.

Request Your Free Anthrax Vaccine Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

Who Are the Key Firms Paving the Way for Growth in the Anthrax Vaccine Market?

Major companies operating in the anthrax vaccine market are:

• Merck & Co. Inc.

• GC Biopharma

• Emergent BioSolutions Inc.

• Indian Immunologicals Limited

• Valneva SE

What Are the Most Influential Trends Currently Shaping the Anthrax Vaccine Market?

Market leaders in the anthrax vaccine industry are concentrating on creating novel products and securing FDA endorsements for their vaccines to assure their safety, effectiveness, and accessibility to those susceptible to anthrax exposure. Acquiring approval from the FDA guarantees that the vaccine has undergone rigorous clinical trial testing and is verified as safe for public consumption, thereby shielding people from any possible harmful effects. As a case in point, Emergent BioSolutions Inc., a biopharmaceutical company based in the US, in July 2023, achieved the approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously referred to as AV7909, from the U.S. Food and Drug Administration (FDA). The endorsement was based on information obtained from a Phase 2 trial which assessed Cyfendus’s compatibility with antibacterial drugs and Phase 3 clinical study that compared its immunogenicity and safety with BioThrax, the former anthrax vaccine. Moreover, the production of safer and more potent adjuvants is crucial to resolve issues related to reactogenicity and increase the overall effectiveness of anthrax vaccines.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Which Key Market Segments Comprise the Anthrax Vaccine Market and Drive Its Revenue Growth?

The anthrax vaccine market covered in this report is segmented –

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine

2) By Application Type: Animal Use, Human Use

3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels

Subsegments:

1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine

2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine

Which Regions Are Essential for the Growth of the Anthrax Vaccine Market?

North America was the largest region in the anthrax vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Scope and Reach of the Anthrax Vaccine Market Defined?

The anthrax vaccine is a medical product designed to provide immunity against anthrax, a severe infectious disease caused by the bacterium Bacillus anthracis. The vaccine comprises an inactivated form of the anthrax bacterium or its components, stimulating the body’s immune system to produce antibodies against anthrax toxins. The anthrax vaccine is typically administered through injections, with initial doses followed by booster shots to maintain immunity over time.

Browse Through More Similar Reports By The Business Research Company:

DTP Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

Dog Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Inactivated Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: